#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=In yet another embodiment of the invention encompasses reagents for detecting bacterial infection, including K. pneumoniae infection, which comprise at least one K. pneumoniae-derived nucleic acid defined by any one of SEQ ID NO: 1-SEQ ID NO: 7171, or sequence-conservative or function-conservative variants thereof.
1-1	0-2	In	_	_	
1-2	3-6	yet	_	_	
1-3	7-14	another	_	_	
1-4	15-25	embodiment	_	_	
1-5	26-28	of	_	_	
1-6	29-32	the	_	_	
1-7	33-42	invention	_	_	
1-8	43-54	encompasses	_	_	
1-9	55-63	reagents	_	_	
1-10	64-67	for	_	_	
1-11	68-77	detecting	_	_	
1-12	78-87	bacterial	_	_	
1-13	88-97	infection	_	_	
1-14	97-98	,	_	_	
1-15	99-108	including	_	_	
1-16	109-110	K	_	_	
1-17	110-111	.	_	_	
1-18	112-122	pneumoniae	_	_	
1-19	123-132	infection	_	_	
1-20	132-133	,	_	_	
1-21	134-139	which	_	_	
1-22	140-148	comprise	_	_	
1-23	149-151	at	_	_	
1-24	152-157	least	_	_	
1-25	158-161	one	_	_	
1-26	162-163	K	_	_	
1-27	163-164	.	_	_	
1-28	165-183	pneumoniae-derived	_	_	
1-29	184-191	nucleic	_	_	
1-30	192-196	acid	_	_	
1-31	197-204	defined	_	_	
1-32	205-207	by	_	_	
1-33	208-211	any	_	_	
1-34	212-215	one	_	_	
1-35	216-218	of	_	_	
1-36	219-222	SEQ	_	_	
1-37	223-225	ID	_	_	
1-38	226-228	NO	_	_	
1-39	228-229	:	_	_	
1-40	230-231	1	_	_	
1-41	231-232	-	_	_	
1-42	232-235	SEQ	_	_	
1-43	236-238	ID	_	_	
1-44	239-241	NO	_	_	
1-45	241-242	:	_	_	
1-46	243-247	7171	_	_	
1-47	247-248	,	_	_	
1-48	249-251	or	_	_	
1-49	252-273	sequence-conservative	_	_	
1-50	274-276	or	_	_	
1-51	277-298	function-conservative	_	_	
1-52	299-307	variants	_	_	
1-53	308-315	thereof	_	_	
1-54	315-316	.	_	_	

#Text=Alternatively, the diagnostic reagents comprise nucleotide sequences that are contained within any open reading frames (ORFs), including preferably complete protein-coding sequences, contained within any of SEQ ID NO: 1-SEQ ID NO: 7171, or polypeptide sequences contained within any of SEQ ID NO: 7172-SEQ ID NO: 14342, or polypeptides of which any of the above sequences forms a part, or antibodies directed against any of the above peptide sequences or function-conservative variants and/or fragments thereof.
2-1	317-330	Alternatively	_	_	
2-2	330-331	,	_	_	
2-3	332-335	the	_	_	
2-4	336-346	diagnostic	_	_	
2-5	347-355	reagents	_	_	
2-6	356-364	comprise	_	_	
2-7	365-375	nucleotide	_	_	
2-8	376-385	sequences	_	_	
2-9	386-390	that	_	_	
2-10	391-394	are	_	_	
2-11	395-404	contained	_	_	
2-12	405-411	within	_	_	
2-13	412-415	any	_	_	
2-14	416-420	open	_	_	
2-15	421-428	reading	_	_	
2-16	429-435	frames	_	_	
2-17	436-437	(	_	_	
2-18	437-441	ORFs	_	_	
2-19	441-442	)	_	_	
2-20	442-443	,	_	_	
2-21	444-453	including	_	_	
2-22	454-464	preferably	_	_	
2-23	465-473	complete	_	_	
2-24	474-488	protein-coding	_	_	
2-25	489-498	sequences	_	_	
2-26	498-499	,	_	_	
2-27	500-509	contained	_	_	
2-28	510-516	within	_	_	
2-29	517-520	any	_	_	
2-30	521-523	of	_	_	
2-31	524-527	SEQ	_	_	
2-32	528-530	ID	_	_	
2-33	531-533	NO	_	_	
2-34	533-534	:	_	_	
2-35	535-536	1	_	_	
2-36	536-537	-	_	_	
2-37	537-540	SEQ	_	_	
2-38	541-543	ID	_	_	
2-39	544-546	NO	_	_	
2-40	546-547	:	_	_	
2-41	548-552	7171	_	_	
2-42	552-553	,	_	_	
2-43	554-556	or	_	_	
2-44	557-568	polypeptide	_	_	
2-45	569-578	sequences	_	_	
2-46	579-588	contained	_	_	
2-47	589-595	within	_	_	
2-48	596-599	any	_	_	
2-49	600-602	of	_	_	
2-50	603-606	SEQ	_	_	
2-51	607-609	ID	_	_	
2-52	610-612	NO	_	_	
2-53	612-613	:	_	_	
2-54	614-618	7172	_	_	
2-55	618-619	-	_	_	
2-56	619-622	SEQ	_	_	
2-57	623-625	ID	_	_	
2-58	626-628	NO	_	_	
2-59	628-629	:	_	_	
2-60	630-635	14342	_	_	
2-61	635-636	,	_	_	
2-62	637-639	or	_	_	
2-63	640-652	polypeptides	_	_	
2-64	653-655	of	_	_	
2-65	656-661	which	_	_	
2-66	662-665	any	_	_	
2-67	666-668	of	_	_	
2-68	669-672	the	_	_	
2-69	673-678	above	_	_	
2-70	679-688	sequences	_	_	
2-71	689-694	forms	_	_	
2-72	695-696	a	_	_	
2-73	697-701	part	_	_	
2-74	701-702	,	_	_	
2-75	703-705	or	_	_	
2-76	706-716	antibodies	_	_	
2-77	717-725	directed	_	_	
2-78	726-733	against	_	_	
2-79	734-737	any	_	_	
2-80	738-740	of	_	_	
2-81	741-744	the	_	_	
2-82	745-750	above	_	_	
2-83	751-758	peptide	_	_	
2-84	759-768	sequences	_	_	
2-85	769-771	or	_	_	
2-86	772-793	function-conservative	_	_	
2-87	794-802	variants	_	_	
2-88	803-806	and	_	_	
2-89	806-807	/	_	_	
2-90	807-809	or	_	_	
2-91	810-819	fragments	_	_	
2-92	820-827	thereof	_	_	
2-93	827-828	.	_	_	

#Text=The invention further provides antibodies, preferably monoclonal antibodies, which specifically bind to the polypeptides of the invention.
3-1	829-832	The	_	_	
3-2	833-842	invention	_	_	
3-3	843-850	further	_	_	
3-4	851-859	provides	_	_	
3-5	860-870	antibodies	_	_	
3-6	870-871	,	_	_	
3-7	872-882	preferably	_	_	
3-8	883-893	monoclonal	_	_	
3-9	894-904	antibodies	_	_	
3-10	904-905	,	_	_	
3-11	906-911	which	_	_	
3-12	912-924	specifically	_	_	
3-13	925-929	bind	_	_	
3-14	930-932	to	_	_	
3-15	933-936	the	_	_	
3-16	937-949	polypeptides	_	_	
3-17	950-952	of	_	_	
3-18	953-956	the	_	_	
3-19	957-966	invention	_	_	
3-20	966-967	.	_	_	

#Text=Methods are also provided for producing antibodies in a host animal.
4-1	968-975	Methods	_	_	
4-2	976-979	are	_	_	
4-3	980-984	also	_	_	
4-4	985-993	provided	_	_	
4-5	994-997	for	_	_	
4-6	998-1007	producing	_	_	
4-7	1008-1018	antibodies	_	_	
4-8	1019-1021	in	_	_	
4-9	1022-1023	a	_	_	
4-10	1024-1028	host	_	_	
4-11	1029-1035	animal	_	_	
4-12	1035-1036	.	_	_	

#Text=The methods of the invention comprise immunizing an animal with at least one K. pneumoniae-derived immunogenic component, wherein the immunogenic component comprises one or more of the polypeptides encoded by any one of SEQ ID NO: 1-SEQ ID NO: 7171 or sequence-conservative or function-conservative variants thereof; or polypeptides that are contained within any ORFs, including complete protein-coding sequences, of which any of SEQ ID NO: 1-SEQ ID NO: 7171 forms a part; or polypeptide sequences contained within any of SEQ ID NO: 7172-SEQ ID NO: 14342; or polypeptides of which any of SEQ ID NO: 7172-SEQ ID NO: 14342 forms a part.
5-1	1037-1040	The	_	_	
5-2	1041-1048	methods	_	_	
5-3	1049-1051	of	_	_	
5-4	1052-1055	the	_	_	
5-5	1056-1065	invention	_	_	
5-6	1066-1074	comprise	_	_	
5-7	1075-1085	immunizing	_	_	
5-8	1086-1088	an	_	_	
5-9	1089-1095	animal	_	_	
5-10	1096-1100	with	_	_	
5-11	1101-1103	at	_	_	
5-12	1104-1109	least	_	_	
5-13	1110-1113	one	_	_	
5-14	1114-1115	K	_	_	
5-15	1115-1116	.	_	_	
5-16	1117-1135	pneumoniae-derived	_	_	
5-17	1136-1147	immunogenic	_	_	
5-18	1148-1157	component	_	_	
5-19	1157-1158	,	_	_	
5-20	1159-1166	wherein	_	_	
5-21	1167-1170	the	_	_	
5-22	1171-1182	immunogenic	_	_	
5-23	1183-1192	component	_	_	
5-24	1193-1202	comprises	_	_	
5-25	1203-1206	one	_	_	
5-26	1207-1209	or	_	_	
5-27	1210-1214	more	_	_	
5-28	1215-1217	of	_	_	
5-29	1218-1221	the	_	_	
5-30	1222-1234	polypeptides	_	_	
5-31	1235-1242	encoded	_	_	
5-32	1243-1245	by	_	_	
5-33	1246-1249	any	_	_	
5-34	1250-1253	one	_	_	
5-35	1254-1256	of	_	_	
5-36	1257-1260	SEQ	_	_	
5-37	1261-1263	ID	_	_	
5-38	1264-1266	NO	_	_	
5-39	1266-1267	:	_	_	
5-40	1268-1269	1	_	_	
5-41	1269-1270	-	_	_	
5-42	1270-1273	SEQ	_	_	
5-43	1274-1276	ID	_	_	
5-44	1277-1279	NO	_	_	
5-45	1279-1280	:	_	_	
5-46	1281-1285	7171	_	_	
5-47	1286-1288	or	_	_	
5-48	1289-1310	sequence-conservative	_	_	
5-49	1311-1313	or	_	_	
5-50	1314-1335	function-conservative	_	_	
5-51	1336-1344	variants	_	_	
5-52	1345-1352	thereof	_	_	
5-53	1352-1353	;	_	_	
5-54	1354-1356	or	_	_	
5-55	1357-1369	polypeptides	_	_	
5-56	1370-1374	that	_	_	
5-57	1375-1378	are	_	_	
5-58	1379-1388	contained	_	_	
5-59	1389-1395	within	_	_	
5-60	1396-1399	any	_	_	
5-61	1400-1404	ORFs	_	_	
5-62	1404-1405	,	_	_	
5-63	1406-1415	including	_	_	
5-64	1416-1424	complete	_	_	
5-65	1425-1439	protein-coding	_	_	
5-66	1440-1449	sequences	_	_	
5-67	1449-1450	,	_	_	
5-68	1451-1453	of	_	_	
5-69	1454-1459	which	_	_	
5-70	1460-1463	any	_	_	
5-71	1464-1466	of	_	_	
5-72	1467-1470	SEQ	_	_	
5-73	1471-1473	ID	_	_	
5-74	1474-1476	NO	_	_	
5-75	1476-1477	:	_	_	
5-76	1478-1479	1	_	_	
5-77	1479-1480	-	_	_	
5-78	1480-1483	SEQ	_	_	
5-79	1484-1486	ID	_	_	
5-80	1487-1489	NO	_	_	
5-81	1489-1490	:	_	_	
5-82	1491-1495	7171	_	_	
5-83	1496-1501	forms	_	_	
5-84	1502-1503	a	_	_	
5-85	1504-1508	part	_	_	
5-86	1508-1509	;	_	_	
5-87	1510-1512	or	_	_	
5-88	1513-1524	polypeptide	_	_	
5-89	1525-1534	sequences	_	_	
5-90	1535-1544	contained	_	_	
5-91	1545-1551	within	_	_	
5-92	1552-1555	any	_	_	
5-93	1556-1558	of	_	_	
5-94	1559-1562	SEQ	_	_	
5-95	1563-1565	ID	_	_	
5-96	1566-1568	NO	_	_	
5-97	1568-1569	:	_	_	
5-98	1570-1574	7172	_	_	
5-99	1574-1575	-	_	_	
5-100	1575-1578	SEQ	_	_	
5-101	1579-1581	ID	_	_	
5-102	1582-1584	NO	_	_	
5-103	1584-1585	:	_	_	
5-104	1586-1591	14342	_	_	
5-105	1591-1592	;	_	_	
5-106	1593-1595	or	_	_	
5-107	1596-1608	polypeptides	_	_	
5-108	1609-1611	of	_	_	
5-109	1612-1617	which	_	_	
5-110	1618-1621	any	_	_	
5-111	1622-1624	of	_	_	
5-112	1625-1628	SEQ	_	_	
5-113	1629-1631	ID	_	_	
5-114	1632-1634	NO	_	_	
5-115	1634-1635	:	_	_	
5-116	1636-1640	7172	_	_	
5-117	1640-1641	-	_	_	
5-118	1641-1644	SEQ	_	_	
5-119	1645-1647	ID	_	_	
5-120	1648-1650	NO	_	_	
5-121	1650-1651	:	_	_	
5-122	1652-1657	14342	_	_	
5-123	1658-1663	forms	_	_	
5-124	1664-1665	a	_	_	
5-125	1666-1670	part	_	_	
5-126	1670-1671	.	_	_	

#Text=Host animals include any warm blooded animal, including without limitation mammals and birds.
6-1	1672-1676	Host	_	_	
6-2	1677-1684	animals	_	_	
6-3	1685-1692	include	_	_	
6-4	1693-1696	any	_	_	
6-5	1697-1701	warm	_	_	
6-6	1702-1709	blooded	_	_	
6-7	1710-1716	animal	_	_	
6-8	1716-1717	,	_	_	
6-9	1718-1727	including	_	_	
6-10	1728-1735	without	_	_	
6-11	1736-1746	limitation	_	_	
6-12	1747-1754	mammals	_	_	
6-13	1755-1758	and	_	_	
6-14	1759-1764	birds	_	_	
6-15	1764-1765	.	_	_	

#Text=Such antibodies have utility as reagents for immunoassays to evaluate the abundance and distribution of K. pneumoniae-specific antigens.
7-1	1766-1770	Such	_	_	
7-2	1771-1781	antibodies	_	_	
7-3	1782-1786	have	_	_	
7-4	1787-1794	utility	_	_	
7-5	1795-1797	as	_	_	
7-6	1798-1806	reagents	_	_	
7-7	1807-1810	for	_	_	
7-8	1811-1823	immunoassays	_	_	
7-9	1824-1826	to	_	_	
7-10	1827-1835	evaluate	_	_	
7-11	1836-1839	the	_	_	
7-12	1840-1849	abundance	_	_	
7-13	1850-1853	and	_	_	
7-14	1854-1866	distribution	_	_	
7-15	1867-1869	of	_	_	
7-16	1870-1871	K	_	_	
7-17	1871-1872	.	_	_	
7-18	1873-1892	pneumoniae-specific	_	_	
7-19	1893-1901	antigens	_	_	
7-20	1901-1902	.	_	_	

#Text=In yet another aspect, the invention provides diagnostic methods for detecting K. pneumoniae antigenic components or anti-K. pneumoniae antibodies in a sample.
8-1	1903-1905	In	_	_	
8-2	1906-1909	yet	_	_	
8-3	1910-1917	another	_	_	
8-4	1918-1924	aspect	_	_	
8-5	1924-1925	,	_	_	
8-6	1926-1929	the	_	_	
8-7	1930-1939	invention	_	_	
8-8	1940-1948	provides	_	_	
8-9	1949-1959	diagnostic	_	_	
8-10	1960-1967	methods	_	_	
8-11	1968-1971	for	_	_	
8-12	1972-1981	detecting	_	_	
8-13	1982-1983	K	_	_	
8-14	1983-1984	.	_	_	
8-15	1985-1995	pneumoniae	_	_	
8-16	1996-2005	antigenic	_	_	
8-17	2006-2016	components	_	_	
8-18	2017-2019	or	_	_	
8-19	2020-2026	anti-K	_	_	
8-20	2026-2027	.	_	_	
8-21	2028-2038	pneumoniae	_	_	
8-22	2039-2049	antibodies	_	_	
8-23	2050-2052	in	_	_	
8-24	2053-2054	a	_	_	
8-25	2055-2061	sample	_	_	
8-26	2061-2062	.	_	_	

#Text=K. pneumoniae antigenic components may be detected by known processes, including but not limited to detection by a process comprising: (i) contacting a sample suspected to contain a bacterial antigenic component with a bacterial-specific antibody, under conditions in which a stable antigen-antibody complex can form between the antibody and bacterial antigenic components in the sample; and (ii) detecting any antigen-antibody complex formed in step (i), wherein detection of an antigen-antibody complex indicates the presence of at least one bacterial antigenic component in the sample.
9-1	2063-2064	K	_	_	
9-2	2064-2065	.	_	_	
9-3	2066-2076	pneumoniae	_	_	
9-4	2077-2086	antigenic	_	_	
9-5	2087-2097	components	_	_	
9-6	2098-2101	may	_	_	
9-7	2102-2104	be	_	_	
9-8	2105-2113	detected	_	_	
9-9	2114-2116	by	_	_	
9-10	2117-2122	known	_	_	
9-11	2123-2132	processes	_	_	
9-12	2132-2133	,	_	_	
9-13	2134-2143	including	_	_	
9-14	2144-2147	but	_	_	
9-15	2148-2151	not	_	_	
9-16	2152-2159	limited	_	_	
9-17	2160-2162	to	_	_	
9-18	2163-2172	detection	_	_	
9-19	2173-2175	by	_	_	
9-20	2176-2177	a	_	_	
9-21	2178-2185	process	_	_	
9-22	2186-2196	comprising	_	_	
9-23	2196-2197	:	_	_	
9-24	2198-2199	(	_	_	
9-25	2199-2200	i	_	_	
9-26	2200-2201	)	_	_	
9-27	2202-2212	contacting	_	_	
9-28	2213-2214	a	_	_	
9-29	2215-2221	sample	_	_	
9-30	2222-2231	suspected	_	_	
9-31	2232-2234	to	_	_	
9-32	2235-2242	contain	_	_	
9-33	2243-2244	a	_	_	
9-34	2245-2254	bacterial	_	_	
9-35	2255-2264	antigenic	_	_	
9-36	2265-2274	component	_	_	
9-37	2275-2279	with	_	_	
9-38	2280-2281	a	_	_	
9-39	2282-2300	bacterial-specific	_	_	
9-40	2301-2309	antibody	_	_	
9-41	2309-2310	,	_	_	
9-42	2311-2316	under	_	_	
9-43	2317-2327	conditions	_	_	
9-44	2328-2330	in	_	_	
9-45	2331-2336	which	_	_	
9-46	2337-2338	a	_	_	
9-47	2339-2345	stable	_	_	
9-48	2346-2362	antigen-antibody	_	_	
9-49	2363-2370	complex	_	_	
9-50	2371-2374	can	_	_	
9-51	2375-2379	form	_	_	
9-52	2380-2387	between	_	_	
9-53	2388-2391	the	_	_	
9-54	2392-2400	antibody	_	_	
9-55	2401-2404	and	_	_	
9-56	2405-2414	bacterial	_	_	
9-57	2415-2424	antigenic	_	_	
9-58	2425-2435	components	_	_	
9-59	2436-2438	in	_	_	
9-60	2439-2442	the	_	_	
9-61	2443-2449	sample	_	_	
9-62	2449-2450	;	_	_	
9-63	2451-2454	and	_	_	
9-64	2455-2456	(	_	_	
9-65	2456-2458	ii	_	_	
9-66	2458-2459	)	_	_	
9-67	2460-2469	detecting	_	_	
9-68	2470-2473	any	_	_	
9-69	2474-2490	antigen-antibody	_	_	
9-70	2491-2498	complex	_	_	
9-71	2499-2505	formed	_	_	
9-72	2506-2508	in	_	_	
9-73	2509-2513	step	_	_	
9-74	2514-2515	(	_	_	
9-75	2515-2516	i	_	_	
9-76	2516-2517	)	_	_	
9-77	2517-2518	,	_	_	
9-78	2519-2526	wherein	_	_	
9-79	2527-2536	detection	_	_	
9-80	2537-2539	of	_	_	
9-81	2540-2542	an	_	_	
9-82	2543-2559	antigen-antibody	_	_	
9-83	2560-2567	complex	_	_	
9-84	2568-2577	indicates	_	_	
9-85	2578-2581	the	_	_	
9-86	2582-2590	presence	_	_	
9-87	2591-2593	of	_	_	
9-88	2594-2596	at	_	_	
9-89	2597-2602	least	_	_	
9-90	2603-2606	one	_	_	
9-91	2607-2616	bacterial	_	_	
9-92	2617-2626	antigenic	_	_	
9-93	2627-2636	component	_	_	
9-94	2637-2639	in	_	_	
9-95	2640-2643	the	_	_	
9-96	2644-2650	sample	_	_	
9-97	2650-2651	.	_	_	

#Text=In different embodiments of this method, the antibodies used are directed against a sequence encoded by any of SEQ ID NO: 1-SEQ ID NO: 7171 or sequence-conservative or function-conservative variants thereof, or against a polypeptide sequence contained in any of SEQ ID NO: 7172-SEQ ID NO: 14342 or function-conservative variants thereof.
10-1	2652-2654	In	_	_	
10-2	2655-2664	different	_	_	
10-3	2665-2676	embodiments	_	_	
10-4	2677-2679	of	_	_	
10-5	2680-2684	this	_	_	
10-6	2685-2691	method	_	_	
10-7	2691-2692	,	_	_	
10-8	2693-2696	the	_	_	
10-9	2697-2707	antibodies	_	_	
10-10	2708-2712	used	_	_	
10-11	2713-2716	are	_	_	
10-12	2717-2725	directed	_	_	
10-13	2726-2733	against	_	_	
10-14	2734-2735	a	_	_	
10-15	2736-2744	sequence	_	_	
10-16	2745-2752	encoded	_	_	
10-17	2753-2755	by	_	_	
10-18	2756-2759	any	_	_	
10-19	2760-2762	of	_	_	
10-20	2763-2766	SEQ	_	_	
10-21	2767-2769	ID	_	_	
10-22	2770-2772	NO	_	_	
10-23	2772-2773	:	_	_	
10-24	2774-2775	1	_	_	
10-25	2775-2776	-	_	_	
10-26	2776-2779	SEQ	_	_	
10-27	2780-2782	ID	_	_	
10-28	2783-2785	NO	_	_	
10-29	2785-2786	:	_	_	
10-30	2787-2791	7171	_	_	
10-31	2792-2794	or	_	_	
10-32	2795-2816	sequence-conservative	_	_	
10-33	2817-2819	or	_	_	
10-34	2820-2841	function-conservative	_	_	
10-35	2842-2850	variants	_	_	
10-36	2851-2858	thereof	_	_	
10-37	2858-2859	,	_	_	
10-38	2860-2862	or	_	_	
10-39	2863-2870	against	_	_	
10-40	2871-2872	a	_	_	
10-41	2873-2884	polypeptide	_	_	
10-42	2885-2893	sequence	_	_	
10-43	2894-2903	contained	_	_	
10-44	2904-2906	in	_	_	
10-45	2907-2910	any	_	_	
10-46	2911-2913	of	_	_	
10-47	2914-2917	SEQ	_	_	
10-48	2918-2920	ID	_	_	
10-49	2921-2923	NO	_	_	
10-50	2923-2924	:	_	_	
10-51	2925-2929	7172	_	_	
10-52	2929-2930	-	_	_	
10-53	2930-2933	SEQ	_	_	
10-54	2934-2936	ID	_	_	
10-55	2937-2939	NO	_	_	
10-56	2939-2940	:	_	_	
10-57	2941-2946	14342	_	_	
10-58	2947-2949	or	_	_	
10-59	2950-2971	function-conservative	_	_	
10-60	2972-2980	variants	_	_	
10-61	2981-2988	thereof	_	_	
10-62	2988-2989	.	_	_	

#Text=In yet another aspect, the invention provides a method for detecting antibacterial-specific antibodies in a sample, which comprises: (i) contacting a sample suspected to contain antibacterial-specific antibodies with an K. pneumoniae antigenic component, under conditions in which a stable antigen-antibody complex can form between the K. pneumoniae antigenic component and antibacterial antibodies in the sample; and (ii) detecting any antigen-antibody complex formed in step (i), wherein detection of an antigen-antibody complex indicates the presence of antibacterial antibodies in the sample.
11-1	2990-2992	In	_	_	
11-2	2993-2996	yet	_	_	
11-3	2997-3004	another	_	_	
11-4	3005-3011	aspect	_	_	
11-5	3011-3012	,	_	_	
11-6	3013-3016	the	_	_	
11-7	3017-3026	invention	_	_	
11-8	3027-3035	provides	_	_	
11-9	3036-3037	a	*[1]	12-5[2_1]	
11-10	3038-3044	method	*[1]	_	
11-11	3045-3048	for	*[1]	_	
11-12	3049-3058	detecting	*[1]	_	
11-13	3059-3081	antibacterial-specific	*[1]	_	
11-14	3082-3092	antibodies	*[1]	_	
11-15	3093-3095	in	*[1]	_	
11-16	3096-3097	a	*[1]	_	
11-17	3098-3104	sample	*[1]	_	
11-18	3104-3105	,	_	_	
11-19	3106-3111	which	_	_	
11-20	3112-3121	comprises	_	_	
11-21	3121-3122	:	_	_	
11-22	3123-3124	(	_	_	
11-23	3124-3125	i	_	_	
11-24	3125-3126	)	_	_	
11-25	3127-3137	contacting	_	_	
11-26	3138-3139	a	_	_	
11-27	3140-3146	sample	_	_	
11-28	3147-3156	suspected	_	_	
11-29	3157-3159	to	_	_	
11-30	3160-3167	contain	_	_	
11-31	3168-3190	antibacterial-specific	_	_	
11-32	3191-3201	antibodies	_	_	
11-33	3202-3206	with	_	_	
11-34	3207-3209	an	_	_	
11-35	3210-3211	K	_	_	
11-36	3211-3212	.	_	_	
11-37	3213-3223	pneumoniae	_	_	
11-38	3224-3233	antigenic	_	_	
11-39	3234-3243	component	_	_	
11-40	3243-3244	,	_	_	
11-41	3245-3250	under	_	_	
11-42	3251-3261	conditions	_	_	
11-43	3262-3264	in	_	_	
11-44	3265-3270	which	_	_	
11-45	3271-3272	a	_	_	
11-46	3273-3279	stable	_	_	
11-47	3280-3296	antigen-antibody	_	_	
11-48	3297-3304	complex	_	_	
11-49	3305-3308	can	_	_	
11-50	3309-3313	form	_	_	
11-51	3314-3321	between	_	_	
11-52	3322-3325	the	_	_	
11-53	3326-3327	K	_	_	
11-54	3327-3328	.	_	_	
11-55	3329-3339	pneumoniae	_	_	
11-56	3340-3349	antigenic	_	_	
11-57	3350-3359	component	_	_	
11-58	3360-3363	and	_	_	
11-59	3364-3377	antibacterial	_	_	
11-60	3378-3388	antibodies	_	_	
11-61	3389-3391	in	_	_	
11-62	3392-3395	the	_	_	
11-63	3396-3402	sample	_	_	
11-64	3402-3403	;	_	_	
11-65	3404-3407	and	_	_	
11-66	3408-3409	(	_	_	
11-67	3409-3411	ii	_	_	
11-68	3411-3412	)	_	_	
11-69	3413-3422	detecting	_	_	
11-70	3423-3426	any	_	_	
11-71	3427-3443	antigen-antibody	_	_	
11-72	3444-3451	complex	_	_	
11-73	3452-3458	formed	_	_	
11-74	3459-3461	in	_	_	
11-75	3462-3466	step	_	_	
11-76	3467-3468	(	_	_	
11-77	3468-3469	i	_	_	
11-78	3469-3470	)	_	_	
11-79	3470-3471	,	_	_	
11-80	3472-3479	wherein	_	_	
11-81	3480-3489	detection	_	_	
11-82	3490-3492	of	_	_	
11-83	3493-3495	an	_	_	
11-84	3496-3512	antigen-antibody	_	_	
11-85	3513-3520	complex	_	_	
11-86	3521-3530	indicates	_	_	
11-87	3531-3534	the	_	_	
11-88	3535-3543	presence	_	_	
11-89	3544-3546	of	_	_	
11-90	3547-3560	antibacterial	_	_	
11-91	3561-3571	antibodies	_	_	
11-92	3572-3574	in	_	_	
11-93	3575-3578	the	_	_	
11-94	3579-3585	sample	_	_	
11-95	3585-3586	.	_	_	

#Text=In different embodiments of this method, the antigenic component is encoded by a sequence contained in any of SEQ ID NO: 1-SEQ ID NO: 7171 or sequence-conservative and function-conservative variants thereof, or is a polypeptide sequence contained in any of SEQ ID NO: 7172-SEQ ID NO: 14342 or function-conservative variants thereof.
12-1	3587-3589	In	_	_	
12-2	3590-3599	different	_	_	
12-3	3600-3611	embodiments	_	_	
12-4	3612-3614	of	_	_	
12-5	3615-3619	this	*[2]	_	
12-6	3620-3626	method	*[2]	_	
12-7	3626-3627	,	_	_	
12-8	3628-3631	the	_	_	
12-9	3632-3641	antigenic	_	_	
12-10	3642-3651	component	_	_	
12-11	3652-3654	is	_	_	
12-12	3655-3662	encoded	_	_	
12-13	3663-3665	by	_	_	
12-14	3666-3667	a	_	_	
12-15	3668-3676	sequence	_	_	
12-16	3677-3686	contained	_	_	
12-17	3687-3689	in	_	_	
12-18	3690-3693	any	_	_	
12-19	3694-3696	of	_	_	
12-20	3697-3700	SEQ	_	_	
12-21	3701-3703	ID	_	_	
12-22	3704-3706	NO	_	_	
12-23	3706-3707	:	_	_	
12-24	3708-3709	1	_	_	
12-25	3709-3710	-	_	_	
12-26	3710-3713	SEQ	_	_	
12-27	3714-3716	ID	_	_	
12-28	3717-3719	NO	_	_	
12-29	3719-3720	:	_	_	
12-30	3721-3725	7171	_	_	
12-31	3726-3728	or	_	_	
12-32	3729-3750	sequence-conservative	_	_	
12-33	3751-3754	and	_	_	
12-34	3755-3776	function-conservative	_	_	
12-35	3777-3785	variants	_	_	
12-36	3786-3793	thereof	_	_	
12-37	3793-3794	,	_	_	
12-38	3795-3797	or	_	_	
12-39	3798-3800	is	_	_	
12-40	3801-3802	a	_	_	
12-41	3803-3814	polypeptide	_	_	
12-42	3815-3823	sequence	_	_	
12-43	3824-3833	contained	_	_	
12-44	3834-3836	in	_	_	
12-45	3837-3840	any	_	_	
12-46	3841-3843	of	_	_	
12-47	3844-3847	SEQ	_	_	
12-48	3848-3850	ID	_	_	
12-49	3851-3853	NO	_	_	
12-50	3853-3854	:	_	_	
12-51	3855-3859	7172	_	_	
12-52	3859-3860	-	_	_	
12-53	3860-3863	SEQ	_	_	
12-54	3864-3866	ID	_	_	
12-55	3867-3869	NO	_	_	
12-56	3869-3870	:	_	_	
12-57	3871-3876	14342	_	_	
12-58	3877-3879	or	_	_	
12-59	3880-3901	function-conservative	_	_	
12-60	3902-3910	variants	_	_	
12-61	3911-3918	thereof	_	_	
12-62	3918-3919	.	_	_	

#Text=In another aspect, the invention features a method of generating vaccines for immunizing an individual against K. pneumoniae.
13-1	3920-3922	In	_	_	
13-2	3923-3930	another	_	_	
13-3	3931-3937	aspect	_	_	
13-4	3937-3938	,	_	_	
13-5	3939-3942	the	_	_	
13-6	3943-3952	invention	_	_	
13-7	3953-3961	features	_	_	
13-8	3962-3963	a	_	_	
13-9	3964-3970	method	_	_	
13-10	3971-3973	of	_	_	
13-11	3974-3984	generating	_	_	
13-12	3985-3993	vaccines	_	_	
13-13	3994-3997	for	_	_	
13-14	3998-4008	immunizing	_	_	
13-15	4009-4011	an	_	_	
13-16	4012-4022	individual	_	_	
13-17	4023-4030	against	_	_	
13-18	4031-4032	K	_	_	
13-19	4032-4033	.	_	_	
13-20	4034-4044	pneumoniae	_	_	
13-21	4044-4045	.	_	_	

#Text=The method includes: immunizing a subject with an K. pneumoniae polypeptide, e.g., a surface or secreted polypeptide, or a combination of such peptides or active portion(s) thereof, and a pharmaceutically acceptable carrier.
14-1	4046-4049	The	_	_	
14-2	4050-4056	method	_	_	
14-3	4057-4065	includes	_	_	
14-4	4065-4066	:	_	_	
14-5	4067-4077	immunizing	_	_	
14-6	4078-4079	a	_	_	
14-7	4080-4087	subject	_	_	
14-8	4088-4092	with	_	_	
14-9	4093-4095	an	_	_	
14-10	4096-4097	K	_	_	
14-11	4097-4098	.	_	_	
14-12	4099-4109	pneumoniae	_	_	
14-13	4110-4121	polypeptide	_	_	
14-14	4121-4122	,	_	_	
14-15	4123-4126	e.g	_	_	
14-16	4126-4127	.	_	_	
14-17	4127-4128	,	_	_	
14-18	4129-4130	a	_	_	
14-19	4131-4138	surface	_	_	
14-20	4139-4141	or	_	_	
14-21	4142-4150	secreted	_	_	
14-22	4151-4162	polypeptide	_	_	
14-23	4162-4163	,	_	_	
14-24	4164-4166	or	_	_	
14-25	4167-4168	a	_	_	
14-26	4169-4180	combination	_	_	
14-27	4181-4183	of	_	_	
14-28	4184-4188	such	_	_	
14-29	4189-4197	peptides	_	_	
14-30	4198-4200	or	_	_	
14-31	4201-4207	active	_	_	
14-32	4208-4215	portion	_	_	
14-33	4215-4216	(	_	_	
14-34	4216-4217	s	_	_	
14-35	4217-4218	)	_	_	
14-36	4219-4226	thereof	_	_	
14-37	4226-4227	,	_	_	
14-38	4228-4231	and	_	_	
14-39	4232-4233	a	_	_	
14-40	4234-4250	pharmaceutically	_	_	
14-41	4251-4261	acceptable	_	_	
14-42	4262-4269	carrier	_	_	
14-43	4269-4270	.	_	_	

#Text=Such vaccines have therapeutic and prophylactic utilities.
15-1	4271-4275	Such	_	_	
15-2	4276-4284	vaccines	_	_	
15-3	4285-4289	have	_	_	
15-4	4290-4301	therapeutic	_	_	
15-5	4302-4305	and	_	_	
15-6	4306-4318	prophylactic	_	_	
15-7	4319-4328	utilities	_	_	
15-8	4328-4329	.	_	_	
